Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Thursday, July 13th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) --...
Pharmaceutical
F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, an invoX company (“F-star”), today announced that it has entered into...
Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors
NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the...
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of...
Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
Daré to receive $1 million in July 2023 and $181.8 million in potential milestone payments from Organon under XACIATO global license...
Orion publishes Half-Year Financial Report for January–June 2023 on Monday 17 July 2023
ORION CORPORATION PRESS RELEASE 4 July 2023 at 12.00 EEST Orion publishes Half-Year Financial Report for January–June 2023 on Monday...
IBT announces outcome of its rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES...
Timber Pharmaceuticals Discloses Communication From NYSE American
WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American:...
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks...
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CLEVELAND, July 03, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has raised $25 million...
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for...
Zymeworks Announces Participation in Upcoming Investor Conference
VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional...
Nevakar Injectables Announces FDA Approval of Cyclophosphamide RTD Solution
-- Ready-to-dilute, multi-dose vials reduce compounding time and waste -- BRIDGEWATER, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Nevakar Injectables...
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023
SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that...
Fortrea Launches as Leading, Global Contract Research Organization Positioned to Bring Life-Changing Therapies to Patients Faster
Company completes spin-off from Labcorp and begins trading on Nasdaq under ticker “FTRE” Independent company positioned to capitalize on growth...
Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab...
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on...
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
Madrigal expects to complete full submission of the New Drug Application in July 2023CONSHOHOCKEN, Pa., June 30, 2023 (GLOBE NEWSWIRE)...